Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo: Sales Down 5.3% due to One-time Effects of Merger
May 26, 2008
- I'rom to Market Ranbaxy's Generic Amlodipine
May 26, 2008
- Astellas: Tough Year Expected in FY2008 due to Prograf Patent Expiration
May 26, 2008
- Will Generics Take Off? (4)
May 26, 2008
- Takeda's R&D Spending to Hit Record High of \485 Bil. in FY2008
May 26, 2008
- BUSINESS NEWS IN BRIEF
May 26, 2008
- Takeda Completes Acquisition of Millennium
May 26, 2008
- Toho Pharm.: Record-High Sales and Profits
May 26, 2008
- Kyowa Hakko Kirin Aims at Becoming Global Specialty Pharma Leveraging Biotechnology
May 26, 2008
- Suzuken: Sales Up 8.7% for Wholesale Business
May 26, 2008
- All-Patient Survey Confirms Enbrel's Safety, Efficacy
May 26, 2008
- Alfresa: Sales Up 11.3% to \1,769 Bil.
May 26, 2008
- Mediceo Paltac: Sales Up 4.1% to \2,255 Bil.
May 26, 2008
- Divergent Opinions on Japanese Version of FDA among LDP Members
May 19, 2008
- Daiichi Sankyo to Apply for Combination of Olmetec and Calblock
May 19, 2008
- Banyu's Isentress Roughly Recommended for Approval
May 19, 2008
- MEDICAL DEVICE NEWS IN BRIEF
May 19, 2008
- Committee Recommends Approval of Pfizer's Macugen
May 19, 2008
- R&D NEWS IN BRIEF
May 19, 2008
- BUSINESS NEWS IN BRIEF
May 19, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…